Debate at Brazilian Endocrinology Congress Questions If GLP-1 Therapy Should Be Lifelong
At the 37th Brazilian Congress of Endocrinology and Metabolism, experts debated whether GLP-1 receptor agonists should be lifelong treatments. While some argue indefinite use is necessary to prevent weight regain and maintain cardiometabolic benefits, others advocate for individualized tapering or discontinuation for patients who maintain weight through lifestyle changes. Recent data suggests these drugs primarily reduce fat while preserving muscle, though long-term safety and access remain critical concerns.